key: cord-0695040-ld3j3zbe authors: Holt, Daniel B.; Lardaro, Thomas; Wang, Alfred Z.; Musey, Paul I.; Trigonis, Russell; Bucca, Antonino; Croft, Alexander; Glober, Nancy; Peterson, Kelli; Schaffer, Jason T.; Hunter, Benton R. title: Fluid Resuscitation and Progression to Renal Replacement Therapy in Patients with COVID-19 date: 2021-10-28 journal: J Emerg Med DOI: 10.1016/j.jemermed.2021.10.026 sha: 1bfd1178e8dd2c31cfad4ba180a3b4fba625c48e doc_id: 695040 cord_uid: ld3j3zbe Background Coronavirus disease (COVID-19) is associated with respiratory symptoms and renal effects. Data regarding fluid resuscitation and kidney injury in COVID-19 is lacking and understanding this relationship is critical. Objectives To determine if there is an association between fluid volume administered in 24 hours and development of renal failure in COVID-19 patients. Methods Retrospective chart review; 14 hospitals in Indiana. Included patients ≥18 years old, admitted between March 11, 2020 and April 13, 2020 with a positive test for SARS-CoV-2 within 3 days of admission. Patients requiring renal replacement therapy prior to admission were excluded. Volumes and types of resuscitative intravenous fluids in the first 24 hours were obtained with demographics, medical history, and other objective data. The primary outcome was initiation of renal replacement therapy. Logistic regression modeling was utilized in creating multivariate models for determining factors associated with the primary outcome. Results The fluid volume received in the first 24 hours from hospital admission was associated with initiation of renal replacement therapy in two different multi-variate logistic regression models. An odds ratio of 1.42 (CI 1.01 – 1.99) was observed when adjusting for age, heart failure, obesity, creatinine, bicarbonate, and total fluid volume. An odds ratio of 1.45 (CI 1.02 – 2.05) was observed when variables significant in univariate analysis were adjusted for. Conclusions Each liter of intravenous fluid administered to patients with COVID-19 in the first 24 hours of presentation was independently associated with an increased risk for initiation of renal replacement therapy, supporting judicious fluid administration in patient with this disease. The fluid volume received in the first 24 hours from hospital admission was associated with initiation of renal replacement therapy in two different multi-variate logistic regression models. An odds ratio of 1.42 (CI 1.01 -1.99) was observed when adjusting for age, heart failure, obesity, creatinine, bicarbonate, and total fluid volume. An odds ratio of 1.45 (CI 1.02 -2.05) was observed when variables significant in univariate analysis were adjusted for. Each liter of intravenous fluid administered to patients with COVID-19 in the first 24 hours of presentation was independently associated with an increased risk for initiation of renal replacement therapy, supporting judicious fluid administration in patient with this disease. With hundreds of millions of infected individuals and millions of deaths, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coronavirus disease (COVID-19) pandemic continues to profoundly impact the global community. 1 Despite its prevalence, given the novel nature of this virus, guidelines for the evaluation and management of individuals infected with COVID-19 are limited. Many treatment recommendations are extrapolated from patients with other disease processes. 2 COVID-19, especially in more severe cases, is most commonly associated with pulmonic symptoms with >50% of symptomatic patients experiencing cough and >30% dyspnea. 3 The frequent need for respiratory support in hospitalized patients has led to much research regarding respiratory evaluation and management. Additionally, SARS-CoV-2 can result in significant damage to the kidneys. Prevalence estimates for acute kidney injury (AKI) in the setting of COVID-19 vary widely from 1% -46%, with 1.5 -9.0% of these patients requiring renal replacement therapy (RRT) in severe disease. [4] [5] The etiology for renal dysfunction is likely multi-factorial and a variety of mechanisms, including but not limited to, thromboses, inflammation, direct viral effects, and hypovolemia, have been proposed. 6 Unsurprisingly, AKI is associated with higher mortality rates in patients with While the Surviving Sepsis Campaign (SSC) has issued statements regarding COVID-19 management, covering a breadth of topics including infection control, hemodynamics, ventilation, and various therapies 8 , there is a paucity of direct evidence regarding the prevention and optimal treatment of COVID-19 induced AKI. However, the SSC guidelines recommend a conservative fluid strategy based on previous studies comparing conservative to liberal fluid administration among patients with acute respiratory distress syndrome (ARDS) which patients with COVID-19 are at risk for. These studies have shown increased ventilator-free days and decreased length of stay and no difference in progression to renal failure with conservative fluid resuscitation. [9] [10] Given the morbidity and mortality associated with kidney injury, understanding the impact of resuscitation and fluid management on progression to renal failure in patients with COVID-19 is critical. The primary objective of this study was to determine if there is an association between the volume of resuscitative fluid in the first 24 hours from presentation and development of renal failure in patients admitted with COVID-19. This is a retrospective chart review deemed to be exempt research by the local institutional review board. The study examined data from a large integrated health system encompassing 14 hospitals across the state of Indiana. The combined annual volume of patients seen across the system is in excess of 400,000 with individual facility ranges from 6,000 to 90,000. To be eligible for inclusion, patients had to be adults (≥18 years of age), admitted to the hospital directly from the emergency department (ED) between March 11, 2020 and April 13, 2020, and have a positive polymerase chain reaction (PCR) test for SARS-CoV-2 within 3 days of admission. Patients with a PCR test obtained greater than 3 days after hospital admission were excluded, as they may have been infected in the hospital after being admitted. Patients requiring renal replacement therapy prior to admission were also excluded. A list of eligible patients admitted during the study period was queried from the electronic medical record, Cerner. Then trained data abstractors review reviewed the records of each patient and entered the required data into a standard form in REDCap, our secure data collection instrument. 13 Extracted data included days from symptom onset to ED presentation, age, gender, comorbidities, ED vital signs, laboratory values (culture and chest imaging results), and level of care at the time of admission. Chest imaging results were based on final radiologist interpretation, and were labeled as "clear," "single lobe infiltrates," "multi-lobar infiltrates," or "clear x-ray with involvement on CT only." Vital signs included initial and final ED blood pressure, heart rate, oxygen saturation, temperature, and respiratory rate. If an ambulatory oxygen saturation was documented in the electronic medical record (EMR), it was extracted and recorded separately. Comorbidities were based on chart review of the ED note, admission note, and any clinic or primary care notes available in the EMR. The following comorbidities were recorded for each patient: smoking, obesity, hypertension, diabetes, hyperlipidemia, heart failure, previous ischemic heart disease, active cancer, dialysis dependent renal disease, chronic obstructive pulmonary disease (COPD), asthma, active cancer, current chemotherapy, HIV, history of organ transplantation, and current use of oral immunosuppressants. The primary outcome was initiation of RRT during hospitalization. We assessed the relationship between the total volume of intravenous fluids received during the first 24 hours and initiation of RRT while hospitalized. Patients with newly required RRT during hospitalization were identified via chart review. Reviewers determined volumes via chart review using standardized data extraction forms. The first 24 hours was defined as starting at the time of presentation to the ED. Medication (non-crystalloid or non-colloid) drips and blood products were excluded from the calculation of total volume. In addition to total volume of intravenous fluid, abstractors separately calculated the amount of normal saline, lactated ringers, plasmalyte, and albumin that was administered to each patient. Any other type of crystalloid and/or colloid fluid that was administered in the first 24 hours was included in the calculation for total volume, but not recorded separately. In univariate analyses, we compared demographic, laboratory, clinical findings, and total volume of fluid given in the first 24 hours between patients who did and did not require RRT. To test the independent association between fluid volume and need for RRT, we performed 2 different multivariate regression analyses. In the first, we included variables commonly associated with RRT or COVID-19 outcomes (age, heart failure, obesity, creatinine, bicarbonate, lactate, and total fluid volume in first 24 hours). 14, 15 In the second model, only variables (among those listed above) that were statistically associated (at a p value of 0.05) with the outcome were included. Remdesevir was not available in our system in March and April 2020. No patients in this study received remdesevir, so it was not included in our models. Comparisons of means conducted with two-sided t test or analysis of variance if standard deviations or Bartlett's tests were not found to be significantly different. For means with unequal variances, a two-sided t-test for unequal variances was conducted. Categorical data were compared based on CRRT results with Fisher's exact test. All statistical analyses were performed using Stata/IC 16.1 (StataCorp LLC, College Station, Texas). There were 542 adults with a positive COVID-19 PCR test admitted during the study period. Of these, 17 had documented end stage renal disease prior to presentation and were excluded. Demographic data for the 525 patients included in the study is provided in Table 1 . Twenty-three patients (4.4%) underwent initiation of RRT during hospitalization. Patients started on RRT during hospitalization were similar age (62.9 vs 60.3 years; P = 0.31) but tended to be more often male (69.6% vs 49.8%; P = 0.057), compared to those who did not undergo RRT. Regarding comorbidities, more patients started on RRT were documented as taking immunosuppressive medications (17.4% vs 5.2%; P = 0.040). No other statistically significant differences in medical comorbidities were identified, although nearly all comorbidities were more frequent in patients requiring RRT. Vital signs and chest radiographic data were similar between patients started on RRT and those not requiring RRT during hospitalization ( Table 2) . Select laboratory results, stratified by those patients for which RRT was initiated, are also displayed. Statistically significant differences in presenting potassium (4. Table 3 . This was consistent among all types of fluids recorded, with the largest difference in balanced solutions of lactated ringers (599 ml vs. 352 ml; P = 0.24) and plasmalyte (289 ml vs. 21 ml; P = 0.18). Table 4 , patients who progressed to RRT during admission were more often intubated (95.7% vs 27.3%; P < 0.001) and were more likely to be intubated within the first 24 hours of admission (43.5% vs 16.3%; P = 0.0030). These patients were more frequently admitted to the ICU (28.6% vs 9.8%; P = 0.048) and had a higher rate of death during hospitalization (43.5% vs 12.8%; P < 0.001). In regression models, we tested for associations between RRT and the following Table 5 . In patients admitted with PCR confirmed COVID-19, each liter of resuscitative crystalloid given during the first 24 hours of hospitalization was independently associated with receiving RRT. This correlation was persistent across two different multi-variate logistic regression models. Of note, the patients progressing to renal failure in this study received greater amounts of each of the commonly utilized crystalloid resuscitative fluids (normal saline, lactated ringers, and plasmalyte). Various mechanisms for COVID-19 induced kidney injury have been proposed, including acute tubular necrosis secondary to shock and poor perfusion. 5, 7, 16 Acute kidney injury and the progression to renal failure is well known as an independent risk factor for in-hospital mortality, including in patients with COVID-19. 5, 17 Conservative strategies for fluid resuscitation have been recommended in the treatment of patients with COVID-19, 8 primarily for theoretical lung protection, however no data exists regarding the ideal fluid resuscitation volume and its effect on renal function in this patient population. This lack of evidence can create challenging scenarios for clinicians faced with treating COVID-19 patients. Current guidelines proposed by the SSC call for judicious fluid administration, 18 but clinicians may instinctively reach for crystalloid resuscitation in patients who may present similarly to those with bacterial sepsis. Patients with COVID-19 may present hypovolemic or poorly perfused, creating a conundrum whereby the usual method for resuscitation may create harm by worsening respiratory status. This study adds further data to the debate around how to approach these patients, in showing that more aggressive early fluid resuscitation is also associated with renal failure and being started on RRT during hospitalization. There are several important limitations to this study. First, this data is observational, and the results could have been driven by unmeasured confounders. Patients who went on to require RRT had higher baseline creatinine and lower bicarbonate levels, among other markers of baseline illness. As such, providers may have been compelled to try to resuscitate them more aggressively. While we performed multiple versions of logistic regression to try to account for these baseline imbalances, other unmeasured confounders may have contributed to our finding of an association between fluid volume and need for RRT. Only patients with PCR-confirmed COVID-19 within 3 days of hospital admission were included. The system at the time of this study was testing nearly all admitted patients for COVID-19, however this would exclude patients that may have presented with COVID-19 like symptoms but were not tested within the defined period of 3 days. However, we found only 3 cases of patients admitted with a first positive COVID-19 PCR drawn after 3 days, so it is likely that very few patients were missed for this reason. Regarding fluids, only intravenous fluids documented in the EMR as having been administered as a bolus or as maintenance fluids were included. Our EMR's data entry system allowed for specification of the amount of normal saline, lactated ringers, and/or plasmalyte given, but not other fluid types. However, all other bolus and maintenance fluids were included in total intravenous fluids given and were a small proportion of the total fluids administered. Only 9 patients were found to have received non-blood product IV fluids outside of those 3 formulations, all in small amounts. Given inconsistencies in the entry of urine output in the EMR, we were unable to reliably measure net fluid balance. We collected fluid totals for the first 24 hours of the hospital stay for each individual patient. We are unable to reliably determine whether these fluids represent primarily fluid boluses received in the ED or were given over longer periods of time as maintenance fluids or repeated small boluses. It is possible that there is a difference in the effect of aggressive fluid boluses in the first hours of resuscitation versus that of spreading out IV fluid volume over the initial 24 hours. Laboratory and imaging work-up was provider dependent, leading to instances of data that was not collected. Notably, lactate levels were not obtained in nearly half of the cohort. We had planned to include lactate levels in our initial multivariate logistic regression model, but had to exclude it due to so many missing data points. Among those who did have a lactate level drawn, it was not associated with the primary outcome. Patients without any bolus or maintenance fluids documented in the EMR were presumed to have received 0 intravenous fluids in our data and calculations. However, system policy is such that documentation of fluids given is required, so we expect this to be an accurate assumption. Lastly, we had a small number of cases (23) requiring RRT among the study population, resulting in relatively wide confidence intervals which came very close to the line of no effect, weakening confidence that the association between fluid volume and RRT represent any type of cause and effect relationship. Additionally, with so few cases, the validity of including 6 variables in one of our regression models is questionable. However, we felt it important to try to account for those factors which are strongly associated with outcomes including RRT in COVID-19. Given that this data was collected from one healthcare system located in one state, the generalizability of these results may be limited as well. Among patients with PCR-confirmed COVID-19 infection, each liter of crystalloid received in the first 24 hours from presentation was independently associated with an increased risk of renal failure requiring RRT. While these results support judicious administration of intravenous fluid volumes during the resuscitation of patients with COVID-19, confidence in this association is limited due to small sample size, wide confidence intervals and the limitations of this observational data set. Further prospective studies, controlling for fluid types, volume of resuscitation, and monitoring of patient fluid balance, are needed. 1) Why is this topic important? a. Patients with COVID-19 may experience harmful renal effects. The impact of fluid resuscitation on renal function in patients with COVID-19 is not well understood and data is sparse. 2) What does this study attempt to show? a. That there is an association between the volume of fluids administered in resuscitating patients with COVID-19 and renal impairment. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. World Health Organization website Management of Critically Ill Adults With COVID-19 Predictors of mortality in patients with COVID-19-a systematic review COVID-19 and the kidney: what we think we know so far and what we don't COVID-19 and Renal Failure: Challenges in the Delivery of Renal Replacement Therapy What every Intensivist should know about COVID-19 associated acute kidney injury Kidney disease is associated with in-hospital death of patients with COVID-19 Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis Comparison of two fluid-management strategies in acute lung injury Can we predict which COVID-19 patients will need transfer to intensive care within 24 hours of floor admission? Acad Emerg Med Characteristics of COVID-19 patients with bacterial coinfection admitted to the hospital from the emergency department in a large regional healthcare system Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support Factors Associated with Unplanned Dialysis Starts in Patients followed by Nephrologists: A Retropective Cohort Study Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies Risk factors and prognosis for COVID-19-induced acute kidney injury: a meta-analysis Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia Management of Sepsis and Septic Shock